Anticoagulation for Atrial Fibrillation: What to Start
Start a direct oral anticoagulant (DOAC)—specifically apixaban, dabigatran, edoxaban, or rivaroxaban—as the preferred anticoagulant for patients with atrial fibrillation requiring stroke prevention based on their CHA₂DS₂‑VASc score. 1
When to Initiate Anticoagulation
The 2024 ESC guidelines provide clear thresholds based on the CHA₂DS₂‑VASc score (note: the newest guidelines have simplified this to CHA₂DS₂‑VA, removing the sex category):
- CHA₂DS₂‑VA = 0: No anticoagulation needed
- CHA₂DS₂‑VA = 1: Anticoagulation should be considered
- CHA₂DS₂‑VA ≥ 2: Anticoagulation is recommended 1
This represents a shift from older scoring systems. Research demonstrates that even patients with a score of 1 have annual stroke rates of 2.62-2.76%, which justifies anticoagulation consideration 2. The risk varies by which specific factor contributes to the score, with age 65-74 years carrying the highest stroke rate (3.33-3.38%/year) 2.
First-Line Agent Selection
DOACs are preferred over warfarin for all patients except two specific situations 1:
Choose a DOAC when:
- The patient has nonvalvular atrial fibrillation
- No mechanical heart valve is present
- No moderate-to-severe mitral stenosis exists
The four DOACs have equivalent Class I recommendations:
- Apixaban
- Dabigatran
- Edoxaban
- Rivaroxaban
All four have demonstrated at least non-inferiority to warfarin for stroke prevention, with generally lower bleeding rates, particularly for intracranial hemorrhage 3.
When Warfarin is Required
Use warfarin (INR target 2.0-3.0) only in these situations 1:
- Mechanical heart valves (dabigatran is contraindicated and harmful in this population 3)
- Moderate-to-severe mitral stenosis
Note: Patients with bioprosthetic valves should receive DOACs, not warfarin 3.
Dosing Considerations
Use full standard doses of DOACs unless specific dose-reduction criteria are met 1. Each DOAC has its own dose-reduction criteria based on:
- Renal function (must be assessed before initiation and at least annually) 3
- Age
- Body weight
- Drug interactions
For edoxaban specifically, the ENGAGE-TIMI 48 trial showed that 60 mg once daily was superior to warfarin (1.2% vs 1.5% annual stroke rate), while 30 mg was non-inferior but with significantly lower bleeding (1.6% vs 3.4% major bleeding) 3.
Critical Safety Points
Before Starting Anticoagulation:
- Evaluate renal function (required for DOAC dosing and contraindications)
- Evaluate hepatic function
- Assess bleeding risk factors to optimize safety, but do not use bleeding risk scores to withhold anticoagulation 1, 3
Special Population: End-Stage Renal Disease
For patients with CrCl <15 mL/min or on dialysis with CHA₂DS₂‑VASc ≥2 (men) or ≥3 (women), it may be reasonable to use either:
- Warfarin (INR 2.0-3.0), or
- Apixaban (the only DOAC with some data in this population) 3
Pattern of AF Does Not Matter
The type of atrial fibrillation—paroxysmal, persistent, or permanent—does not change anticoagulation decisions. Stroke risk stratification and anticoagulant selection should be based solely on the CHA₂DS₂‑VASc score, not the AF pattern 3, 4.
What NOT to Do
Do not use antiplatelet therapy alone (aspirin or clopidogrel) for stroke prevention in AF—there is no role for this approach 1, 4. Only combine anticoagulation with antiplatelet agents when:
- Acute vascular event occurs (e.g., acute coronary syndrome)
- Interim treatment needed for procedures
Switching from Warfarin to DOAC
Switch from warfarin to a DOAC if 1:
- Risk of intracranial hemorrhage is elevated
- Poor INR control (time in therapeutic range <70%)
Ongoing Management
Reassess stroke and bleeding risks at periodic intervals to ensure continued appropriateness of anticoagulation choice and dose 1, 3. This includes annual renal function monitoring at minimum for DOAC patients 3.
The evidence strongly supports DOACs as first-line therapy for the vast majority of AF patients requiring anticoagulation, with warfarin reserved only for mechanical valves and significant mitral stenosis. The net clinical benefit of DOACs over warfarin is well-established, particularly regarding reduced intracranial bleeding risk 5.